Embracing Future Holdings Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions in Singapore, China, and Hong Kong. It operates through Cancer, Infectious Diseases, E-Sports, and Advertising segments. The company offers ClearCell FX1 System that includes Streck Cell-free DNA BCT and EDTA tubes, a fully automated device for cell retrieval that can separate wholly intact and viable circulating tumour cells, or CTCs from small amounts of blood; and CTChip FR1 biochip that isolate the CTCs from leukocytes. It also engages in technology development, technology transfer, marketing, sale and distribution of biomedical technology, life and medicine science related products and services, integrated marketing services provider in the gaming industry, multi-channel networking and live-streaming and investment activities. The company was formerly known as Biolidics Limited and changed its name to Embracing Future Holdings Limited in June 2025. Embracing Future Holdings Limited was incorporated in 2009 and is based in Singapore.